O V Androfagina focuses on how well the drug Revelise works for patients who have experienced ischemic strokes, which occur when a blood clot blocks blood flow to the brain. Their research evaluates not only the drug's efficacy but also its safety in older patients and those with existing health problems. This work is crucial for doctors looking to improve recovery outcomes for stroke patients and supports better treatment strategies for this serious condition.
Key findings
In a study involving 2,202 patients, nearly half (49.9%) of patients had good outcomes at discharge after receiving Revelise.
Good outcome rates increased to 66.4% after 90 days, demonstrating a significant long-term benefit of the treatment.
The study included a predominantly older patient population, indicating the drug's effectiveness even among those with additional health complications.
Frequently asked questions
Does Dr. Androfagina study ischemic stroke?
Yes, Dr. Androfagina specializes in researching treatments for ischemic stroke, specifically using the drug Revelise.
What treatments has Dr. Androfagina researched?
Dr. Androfagina has researched the use of Revelise, a medication for treating ischemic stroke, looking at its effectiveness and safety.
Is Dr. Androfagina's work relevant to older stroke patients?
Absolutely, their research shows that Revelise is effective for older patients and those with other health issues, enhancing recovery opportunities for this group.
Publications in plain English
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].
2022
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Gusev EI, Martynov MY, Shamalov NA, Yarovaya EB, Semenov MP +36 more
Plain English This study compared two treatments for patients suffering from acute ischemic stroke: non-immunogenic staphylokinase (NS) and alteplase (A). Out of 336 patients, 50% of those who received NS had a good recovery after 90 days, while 41% of those who received alteplase did, showing that NS may be a more effective option. It also resulted in fewer serious complications, with 13% of NS patients experiencing significant side effects compared to 22% in the alteplase group.
Who this helps: This helps patients who are dealing with acute ischemic strokes.
[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
2022
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Soldatov MA, Klimov LV, Tolmachev AP, Kiseleva TV, Androfagina OV +17 more
Plain English This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days.
Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.
[Study of the effectiveness of neuroprotective therapy in restoring motor function in patients during the acute period of ischemic stroke].
2021
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Minina YD, Zakharov AV, Poverennova IE, Androfagina OV
Plain English This study looked at how a treatment called Cellex helps patients recover movement after a stroke that affects their ability to move on one side of the body. Researchers tested 60 patients who had suffered a stroke recently and found that those receiving Cellex showed a greater improvement in movement scores compared to those who didn't, with significant gains in specific tests measuring motor function. Notably, by the end of the study, 67% of patients treated with Cellex had mild stroke symptoms, compared to just 11% in the control group.
Who this helps: This benefits stroke patients seeking better recovery outcomes.
[Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
2021
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Soldatov MA, Marskaya NA, Barsegova KA, Androfagina OV, Borisov DN +9 more
Plain English This study looked at the use of a drug called Revelisa for treating ischemic stroke patients in real-life hospital settings. Out of 223 patients treated, 7.1% experienced complications from bleeding in the brain, and 13.9% died during their hospital stay. After treatment, nearly half of the patients (48.2%) showed good recovery at discharge, which is comparable to results from other treatments like alteplase.
Who this helps: Patients who suffer from ischemic strokes.
[The efficacy and safety of Mexidol Forte 250 as part of long-term sequential therapy in patients with carotid stroke].
2020
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Strelnikova IA, Svetkina AA, Androfagina OV
Plain English This study examined how a treatment involving mexidol and mexidol forte helps patients recover from carotid ischemic stroke. Out of 50 patients, those receiving the drug therapy showed much better outcomes: 76% achieved a higher level of daily functioning, compared to 48% in the standard treatment group, and they also had milder cognitive and memory problems. This is important because it shows that using mexidol can significantly improve recovery and quality of life for these patients.
Who this helps: This helps stroke patients by potentially speeding up their recovery and enhancing their daily functioning.
[Mexidol in the rehabilitation of patients in the acute ischemic stroke].
2015
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Androfagina OV, Kuznetsova TV, Svetkina AA
Plain English This study looked at how the drug Mexidol helps patients recover after having an acute ischemic stroke. It analyzed 20 patients and found that using Mexidol led to clear improvements in brain and body functions, such as movement and thinking, as well as reduced feelings of tiredness and anxiety. This matters because better rehabilitation can greatly enhance the quality of life for stroke survivors.
Who this helps: Patients recovering from acute ischemic stroke.
[Preliminary results of the realization of the Federal program on improvement of medical care to stroke patients in the Samara region].
2013
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Androfagina OV, Poverennova IE, Strel'nikova IA, Nekliudova MA
Plain English In the Samara region, heart and blood vessel diseases are the leading cause of death, making up 53% of total deaths. Thanks to a new federal program aimed at improving care for stroke patients, cases of serious blood circulation problems dropped from 343 to 326 per 100,000 people, and the death rate fell from 145.7 to 87.4 per 100,000. Additionally, the number of patients who could care for themselves after being discharged increased from 50.8% in 2010 to 64.2% in 2012, highlighting the program’s success and the need for its continued implementation across the entire area.
Who this helps: Stroke patients and their families.